Improved colon cancer survival rates identified for patients on glp1
New analysis suggests GLP-1 agonists may offer meaningful mortality benefits for people with colon cancer, especially those with higher BMI.
A large retrospective study of nearly 7,000 patients found that people with colon cancer who were taking GLP-1 receptor agonists had less than half the 5-year mortality rate of those not using these obesity drugs.
The benefit appeared strongest in people with BMI over 35, suggesting a possible metabolic link between obesity, inflammation, and cancer out…
